Authors: E BarrettConnor S W Wade T P Do S SatramHoang R Stewart G Gao D Macarios
Publish Date: 2011/04/06
Volume: 23, Issue: 2, Pages: 733-741
Abstract
Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1year period Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67 Treatment satisfaction and side effect experience influence osteoporosis medication adherenceNonadherence is common among women using postmenopausal osteoporosis PMO medications We describe the association between treatment satisfaction measured with the Treatment Satisfaction Questionnaire for Medication TSQM and the risk of discontinuation/switching PMO medications using patientreported data from a large longitudinal cohort studyData from 2405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience POSSIBLE US™ Study were evaluated Cox proportional hazards regression was used to estimate hazard ratios HR for the association between treatment satisfaction at study entry and selfreported discontinuation/switching of pharmacologic PMO medications over a 1year followup period Logistic regression was used to evaluate relationships between treatment satisfaction lifestyle behaviors and compliance with bisphosphonate dosing instructionsMedian TSQM scores were highest indicating greatest satisfaction for the side effects domain n = 1182 median = 875 Q1 = 750 Q3 = 1000 and lowest for global satisfaction n = 2340 median = 640 Q1 = 557 Q3 = 777 Median scores decreased for the side effects and global satisfaction domains as patientreported side effect severity increased Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores adjusted HRs for convenience 073 95 CI = 063–085 effectiveness 082 95 CI = 070–097 and global satisfaction 073 95 CI = 063–085 Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects HR = 060 95 CI = 037–097The authors would like to acknowledge the other members of the POSSIBLE US™ Steering Committee Robert Downs Ted Ganiats Marc Hochberg Barbara Lukert Robert Recker Robert Rubin and Anna Tosteson We would also like to acknowledge the REGISTRAT Inc staff members who assisted with the implementation of this study and ongoing data collection as well as Sue Hudson who provided editorial assistance on behalf of Amgen Inc Funding for this study was provided by Amgen Inc Thousand Oaks CA USAE BarrettConnor receives support from Amgen Inc for serving as Chair of the POSSIBLE US™ Study Steering Committee she is an investigator on clinical trials for Arena Pharmaceuticals Boehringer Ingelheim Merck Pfizer and Roche Dr BarrettConnor also receives grant funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS the National Institute on Aging NIA the National Center for Research Resources NCRR and NIH Roadmap for Medical Research S Wade and S SatramHoang provide consulting services to Amgen Inc T P Do R Stewart G Gao and D Macarios are employees of Amgen Inc and have received Amgen stock/stock options
Keywords: